Detalhe da pesquisa
1.
The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
BMC Health Serv Res
; 22(1): 900, 2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35821026
2.
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Cancer
; 127(9): 1407-1416, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434335
3.
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
Br J Cancer
; 124(4): 713-720, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33191408
4.
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
BMC Cancer
; 21(1): 802, 2021 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253172
5.
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
BMC Cancer
; 21(1): 19, 2021 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33402127
6.
Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea.
J Korean Med Sci
; 36(29): e191, 2021 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34313033
7.
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
BMC Cancer
; 20(1): 1057, 2020 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33143663
8.
Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Oncology
; 96(1): 51-58, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30368503
9.
The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study.
BMC Cancer
; 19(1): 1100, 2019 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31718585
10.
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Cancer Sci
; 109(9): 2852-2862, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29972716
11.
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors.
Oncologist
; 23(2): 155-e17, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158363
12.
Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study.
Support Care Cancer
; 26(7): 2191-2200, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29387994
13.
Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma.
Ann Surg Oncol
; 24(3): 770-777, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27696172
14.
18F-FDG PET/CT and histology for diagnosing recurrent/remnant tumors in head and neck cancer patients treated with radiotherapy.
Hell J Nucl Med
; 20(2): 134-140, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28697190
15.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 17(12): 1643-1652, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27751847
16.
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Invest New Drugs
; 34(5): 625-35, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27350064
17.
Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.
Tumour Biol
; 37(1): 619-25, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26240025
18.
Total Lesion Glycolysis Using ¹8F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer.
J Korean Med Sci
; 31(1): 39-46, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26770036
19.
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer.
Oncologist
; 20(10): 1119-20, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26304911
20.
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Oncologist
; 20(12): 1440-7, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26512046